Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
194 patient asapiprant late treatment RCT: 63% higher mortality (p=0.21), 32% higher ICU admission (p=0.37), 24% higher severe cases (p=0.36), and 33% slower improvement (p=0.17).
RCT 194 hospitalized COVID-19 patients showing no significant differences with asapiprant (BGE-175).
May 2022, NCT04705597, https://clinicaltrials.gov/study/NCT04705597, https://c19p.org/wilkerson
